- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL expects flat Q3 revenues
Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based
Ultrasound vendor ATL reported lastweek that it is not expecting any improvement in third-quarterrevenues due to ongoing difficult market conditions in the U.S.and Europe. According to preliminary internal estimates conductedby the Bothell, WA-based company, third-quarter revenues willprobably be similar to, but will not exceed, those of the secondquarter of this year. ATL reported second-quarter revenue of $84.8million, down 5% compared to the same period a year ago (SCAN8/10/94).
ATL is pinning hopes for a recovery in part on Apogee 800,a mid-range scanner acquired through the vendor's merger withInterspec. ATL is in the midst of a worldwide roll-out of theproduct.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
